TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04615013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Not applicable to this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Not applicable to this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Not applicable to this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Not applicable to this study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hafnium Oxide-containing Nanoparticles NBTXR3
Description: Given IT or IN

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Not applicable to this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Not applicable to this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Not applicable to this study
Study: NCT03673644

Intervention type: OTHER
Intervention: Questionnaires
Description: Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
Study: NCT03456804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
Study: NCT03349073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1101 (Tosylate)
Description: T-1101 (Tosylate) powder in bottle
Study: NCT02166398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI15AML055MT
Description: tab, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amosartan 5/50
Description: tab, PO
Study: NCT05031195

Intervention type: OTHER
Intervention: 1st tertile, 2nd tertile, 3rd tertile
Description: Patients will be divided into 3 groups according to the preoperative NLR value.

Intervention type: OTHER
Intervention: 1st tertile, 2nd tertile, 3rd tertile
Description: Patients will be divided into 3 groups according to the preoperative NLR value.

Intervention type: OTHER
Intervention: 1st tertile, 2nd tertile, 3rd tertile
Description: Patients will be divided into 3 groups according to the preoperative NLR value.
Study: NCT03693612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab
Description: feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: feladilimab
Description: feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
Study: NCT03814733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rapastinel Matched Placebo
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alprazolam Matched Placebo
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine Matched Placebo
Description: Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
Study: NCT02934152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H pylori eradication
Description: H pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H pylori eradication
Description: H pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H pylori eradication
Description: H pylori eradication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H pylori eradication timing
Description: Early or late eradication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H pylori eradication timing
Description: Early or late eradication
Study: NCT03776955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carvedilol
Description: Oral tablet
Study: NCT04969484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth visit
Description: ImPACTT Telehealth visit with the PC provider
Study: NCT02599415

Intervention type: DEVICE
Group type: OTHER
Intervention: TL01 light treatment
Description: Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
Study: NCT01314274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 100mg intranasal submucosal bevacizumab in 10ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: 10ml of 0.9% NaCl intranasal submucosal
Study: NCT03700138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Privigen® 100mg/ml at the dose of 2g/kg of body weight
Description: The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
Study: NCT03148223

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: auriculotherapy
Description: The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auriculotherapy
Description: The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
Study: NCT02824133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: 80 mg bd (per os)
Study: NCT00439205

Intervention type: DEVICE
Intervention: FastEEM4 System
Description: The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.

Intervention type: DEVICE
Intervention: Multispectral Digital Microscope
Description: The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
Study: NCT02807558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Administered as oral tablets
Study: NCT01538342

Intervention type: OTHER
Group type: OTHER
Intervention: 3 Biopsies
Description: 3 biopsies: 2 lesional and 1 non-lesional

Intervention type: OTHER
Group type: OTHER
Intervention: 2 biopsies
Study: NCT02807558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered via intravenous (IV) or subcutaneous (SC) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered via intravenous (IV) or subcutaneous (SC) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered via IV infusion
Study: NCT03811964

Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens

Intervention type: OTHER
Group type: OTHER
Intervention: Specific light exposures
Description: Specific light exposures using light in a wide range of intensities or different light/dark regimens
Study: NCT00126412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-mIBG (meta-iodobenzylguanidine)
Study: NCT03693612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).
Study: NCT03897257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A1 cream
Description: Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A2 cream
Description: Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103B cream
Description: Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A1B cream
Description: Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-103A2B cream
Description: Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).
Study: NCT04348305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days
Study: NCT03256162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
Study: NCT01618864

Intervention type: DEVICE
Group type: OTHER
Intervention: Luxe
Description: Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
Study: NCT02579252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AADvac1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04189718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: osseodensification protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensification protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with osseodensification protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in counter clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant site preparation protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional implant site preparation protocol
Description: Local anaesthesia was administered and mucoperiosteal flap was reflected. Implant osteotomies was performed with sequential drilling with conventional implant site preparation protocol at 1100 rpm. The pilot drill was used in clockwise direction and the other sequential drills were used in clockwise direction under copious irrigation. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
Study: NCT03390205

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography under dark and light adaptation
Description: Optical coherence tomography angiography under dark and light adaptation with pupil dilatation

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography under dark and light adaptation
Description: Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
Study: NCT02503748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online tutorial
Description: website informing about treatment options in localized prostate cancer
Study: NCT01538342

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy
Description: 1 biopsy ok healthy skin
Study: NCT00748007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Exelon (1.5mg/cap) 1.5 mg bid
Study: NCT03693612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.
Study: NCT00748007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivastigmine
Description: Exelon (1.5mg/cap) 1.5 mg bid
Study: NCT02165670

Intervention type: DEVICE
Intervention: Coronary stenting with CE-marked stent
Study: NCT04303949

Intervention type: OTHER
Group type: OTHER
Intervention: Behavioral:
Description: Facilitating couples reduce anxiety, depression and grief through e-book education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral:
Description: Facilitating couples reduce anxiety, depression and grief through e-book education.
Study: NCT02879812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance Feedback Reports
Description: Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video for Staff
Description: Dialysis facility staff will watch a \~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video for Patients
Description: Dialysis facilities will receive a \~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Webinar
Description: Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Dialysis facilities will conduct standard or usual care and education regarding transplantation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: United Network for Organ Sharing (UNOS) Pamphlet
Description: Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
Study: NCT02304874

Intervention type: OTHER
Group type: OTHER
Intervention: Phlebotomy
Study: NCT03693612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.
Study: NCT02879812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: United Network for Organ Sharing (UNOS) Pamphlet
Description: Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
Study: NCT05522725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-use wipes installed at the bedside
Study: NCT02502201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six-minute walk study indoors
Description: Performance of a six-minute walk test according to American Thoracic Society standard.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six-minute walk study indoors
Description: Performance of a six-minute walk test according to American Thoracic Society standard.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: six-minute walk study outdoors
Description: Performance of a six-minute walk test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: six-minute walk study outdoors
Description: Performance of a six-minute walk test.
Study: NCT02821338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine Extended Release
Description: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
Study: NCT02257268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAMOS program - Active life improving health
Description: All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
Study: NCT01799265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnetics Transcend Auto

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnetics Transcend Auto

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics REMstar Auto with C-Flex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respironics REMstar Auto with C-Flex